Generic Name and Formulations:
Levothyroxine sodium 25mcg, 50mcg (dye-free), 75mcg, 88mcg, 100mcg, 112mcg, 125mcg, 150mcg, 175mcg, 200mcg, 300mcg; scored tabs.
Gemini Laboratories, LLC
Indications for UNITHROID:
Take in AM on empty stomach. Hypothyroidism: 1.7mcg/kg once daily. >50yrs, or <50yrs with cardiovascular disease: initially 25–50mcg once daily; titrate in increments of 12.5–25mcg every 4–6 weeks. Elderly with cardiovascular disease: initially 12.5–25mcg once daily; titrate in increments of 12.5–25mcg every 4–6 weeks. Usual max 200mcg/day. Severe hypothyroidism: initially 12.5–25mcg once daily; titrate in increments of 25mcg/day every 4 weeks. Subclinical hypothyroidism, secondary or tertiary hypothyroidism: see literature.
Give once daily on empty stomach. May crush tabs and mix in 5–10mL water. Hypothyroidism: 0–3months: 10–15mcg/kg per day; 3–6months: 8–10mcg/kg per day; 6–12months: 6–8mcg/kg per day; 1–5yrs: 5–6mcg/kg per day; 6–12yrs: 4–5mcg/kg per day; >12yrs: 2–3mcg/kg per day; growth and puberty complete: as adult. Chronic or severe hypothyroidism: initially 25mcg/day; titrate in increments of 25mcg every 4weeks. Infants with serum T4<5mcg/dL: initially 50mcg/day.
Uncorrected adrenal insufficiency. Untreated thyrotoxicosis. Acute MI.
Not for treatment of obesity for weight loss.
Ineffective for weight reduction in euthyroid patients. Not for treatment of infertility. Cardiovascular disease. Seizures. Adrenocortical insufficiency. Increased sensitivity in severe hypothyroidism. Autonomous thyroid tissue. Myxedema coma: use IV levothyroxine. Elderly. Pregnancy (Cat.A); do not discontinue due to pregnancy. Nursing mothers.
See full labeling. Absorption reduced by some foods (eg, soy, fiber), aluminum and magnesium hydroxide, simethicone, calcium carbonate, sodium polystyrene sulfonate, bile acid sequestrants, iron, sucralfate (give at least 4hrs apart). Potentiates, and is potentiated by, tri- and tetracyclic antidepressants, sympathomimetics. Antagonized by hepatic enzyme inducers (eg, carbamazepine, phenytoin, phenobarbital, rifampin), sertraline. Antagonizes digoxin. Marked hypertension and tachycardia with ketamine. Estrogens affect thyroid function tests. Monitor oral anticoagulants, antidiabetic agents, theophylline.
Hyperthyroidism, decreased bone mineral density, transient alopecia; seizures (rare); pseudotumor cerebri in children.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally